Insights from the RESET Clinical Trial: A Post‐Hoc Per Protocol Analysis of Characteristics Associated with Treatment Response Following Percutaneous 60‐Day Medial Branch PNS in Chronic Low Back Pain
PM&R · 2026-11 · 18 (S3)
DOI: 10.1002/pmrj.244_70259 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PM&R, online erschienen am 10.11.2026. Verfasst von Zachary McCormick und 1 weiteren Autor:innen.
Abstract (Originalsprache)
requested the first available provider, were grouped into three cohorts of 150 consecutive patients based on initial provider type: physiatry (PM&R), nurse practitioner/ physician assistant (NP/PA), and spine surgery (orthopedic and neurosurgery).Exclusion Criteria: Patients requesting a specific provider or provider type, presenting for second opinion, or those presenting with prior advanced imaging.
Interventions
Not Applicable Main Outcome Measures: Estimated one-year direct healthcare costs based on rates of physical therapy, spine imaging, spine injections, and spine surgery.
Results
Imaging expenditures were higher in NP/PA ($177,000) and surgeons ($156,000) cohorts, largely driven by greater MRI utilization, compared with the PM&R cohort ($104,250).In contrast, physical therapy was the primary cost driver in the PM&R cohort ($243,000), exceeding costs observed in the NP/PA ($108,000) and surgeon ($162,000) groups.Injection-related costs were comparable between the surgeon ($75,000) and PM&R ($60,000) cohorts but were significantly higher in the NP/PA cohort ($112,000).Surgical costs accounted for the largest expenditure overall, totaling $259,500 in the PM&R cohort, $778,500 in the (NP/PA) cohort, and $1,643,500 in the surgeon cohort.Overall, the estimated total cost per 150 patients was $666,750 for PM&R, $1,175,500 for NP/PA, and $2,036,500 for the surgeon cohort.
Conclusions
Initial provider type was associated with substantial subsequent cost differences, partially driven by MRI utilization, PT referrals, and injections.However, the primary cost driver was the rate of subsequent surgery.Further work is needed to determine the effects on patient outcomes.
Zitieren
APA
McCormick, Z., & Li, S. (2026). Insights from the RESET Clinical Trial: A Post‐Hoc Per Protocol Analysis of Characteristics Associated with Treatment Response Following Percutaneous 60‐Day Medial Branch PNS in Chronic Low Back Pain. PM&R, 18(S3). https://doi.org/10.1002/pmrj.244_70259
Vancouver
McCormick Z, Li S. Insights from the RESET Clinical Trial: A Post‐Hoc Per Protocol Analysis of Characteristics Associated with Treatment Response Following Percutaneous 60‐Day Medial Branch PNS in Chronic Low Back Pain. PM&R. 2026;18(S3). doi:10.1002/pmrj.244_70259
BibTeX
@article{McCormick2026,
author = {McCormick, Zachary and Li, Sean},
title = {Insights from the RESET Clinical Trial: A Post‐Hoc Per Protocol Analysis of Characteristics Associated with Treatment Response Following Percutaneous 60‐Day Medial Branch PNS in Chronic Low Back Pain},
journal = {PM&R},
year = {2026},
volume = {18},
number = {S3},
doi = {10.1002/pmrj.244_70259}
}
EUVIMED